STAT6 degrader

Mechanism

Related News

Kymera Presents Phase 1 KT-621 Data in Japanese Adults, Notes Ongoing Phase 2b Trials

Jun 12, 2026

Kymera Therapeutics presented Phase 1 data for oral STAT6 degrader KT-621 in healthy Japanese adults, showing ≥98% STAT6 degradation and favorable safety. Parallel Phase 2b trials in atopic dermatitis and asthma are ongoing with data expected in 2027, and FDA has granted Fast Track designation for both indications.

Nurix Highlights Oncology and Immunology Degrader Pipeline Progress

May 18, 2026

Nurix reported new oncology preclinical data at AACR 2026 and outlined progress in its immunology degrader pipeline. The company said NX-3911 could enter an IND this year and Phase 1 data for bexobrutideg are planned this year.

Kymera gains FDA Fast Track for KT-621 as Gilead licenses KT-200

Apr 24, 2026

Kymera said the FDA granted Fast Track designation to KT-621 for moderate to severe eosinophilic asthma, while Gilead licensed KT-200 and triggered a $45 million milestone payment.